Atrial fibrillation (AF) is a prevalent and common treatable risk factor for ischemic stroke [1]. The prevalence of AF increases with aging. It has been estimated that the lifetime risk of AF is 1 in 3 after the age of 55 years [1]. AF-associated stroke is associated with higher rates of mortality and disability [2]. Once AF is detected, oral anticoagulation (OAC) is effective in reducing the rates of future stroke [3]. Given that AF episodes are often short-lasting and asymptomatic, AF may be undetected in a significant number of patients, and stroke might be the presenting symptom of undiagnosed AF in about 10–20% of cases [4].
